Nuvation Bio
Nuvation Bio's revenue rose 699.0% to $63 million in fiscal 2025. Its operating margin was −338.7%, up from −7,527.3% a year earlier. Free cash flow was −$181 million. The diluted share count rose 27.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nuvation Bio does
Nuvation Bio is a cancer drug company. It was founded in 2018 by its chief executive, David Hung, who earlier founded Medivation. Its first product is IBTROZI (taletrectinib), a pill for adults with advanced non-small cell lung cancer, the most common form of lung cancer, whose tumors have a gene change called ROS1. The US Food and Drug Administration approved it on June 11, 2025. Nuvation sells it in the United States with its own sales team.
Outside the US it relies on partners. Nippon Kayaku sells taletrectinib in Japan as IBTROZI, and Innovent sells it in China as DOVBLERON. In January 2026 it signed a partnership with Eisai to sell it in Europe and other territories, and it expects to file for approval in Europe in the first half of 2026. It is also running more trials of taletrectinib, including a global Phase 3 study in patients after surgery for early-stage disease.
Its other clinical-stage drug is safusidenib, a pill for a type of brain tumor called IDH1-mutant astrocytoma, which is in a Phase 3 study. It also has early drug candidates from a platform that links two drugs together. Nuvation earns money from US sales of IBTROZI and from its partners. It says it has limited experience as a commercial company.
Its biggest risks, as it describes them
- Its near-term prospects depend heavily on selling IBTROZI successfully in the United States.
- Limited experience as a commercial company, so its sales and marketing may be less successful than planned.
- IBTROZI may not win enough acceptance from doctors, patients and insurers, or its market may be smaller than expected.
- Relying on a select group of distributors and specialty pharmacies, and on partners abroad.
- Failing to keep regulatory approval for IBTROZI, or to win approval for other drugs.
Income statement
Nuvation Bio lost money in fiscal 2025: a net loss of $205 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 765 | 661 | 611 | 503 | 529 |
| Debt incl. finance leases | — | — | — | — | 53 |
| Net debt (negative means net cash) | — | — | — | — | −476 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | 0.2x |
| Interest coverage | — | — | — | −1,737.9x | −15.6x |
| Current ratio | 45.6x | 50.7x | 44.1x | 9.0x | 7.0x |
| Quick ratio | 45.6x | 50.7x | 44.1x | 9.0x | 6.8x |
Cash flow
Projections
Project Nuvation Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Nuvation Bio reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | 410.5% |
| Altman Z'' | 42.31 | −0.84 | −2.01 |
| Accruals ratio | −1.2% | −75.3% | −5.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | — | — |
Compare
Put Nuvation Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | Compare |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | 0 | 8 | 63 |
| Revenue growth | — | — | — | — | — | 699.0% |
| Gross profit | — | — | — | 0 | 1 | — |
| Research and development | 33 | 69 | 88 | 71 | 99 | 115 |
| Operating income | −44 | −93 | −120 | −100 | −593 | −213 |
| Net income | −42 | −87 | −104 | −76 | −568 | −205 |
| Diluted EPS (US$) | −0.43 | −0.44 | −0.48 | −0.35 | −2.11 | −0.60 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow | ||||||
| Cash from operations | −36 | −68 | −96 | −68 | −130 | −173 |
| Capital expenditure | — | — | — | — | 0 | 8 |
| Free cash flow | — | — | — | — | −130 | −181 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 9 | 16 | 20 | 32 | 36 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 216 | 765 | 661 | 611 | 503 | 529 |
| Debt incl. finance leases | — | — | — | — | — | 53 |
| Total assets | 222 | 776 | 672 | 622 | 541 | 595 |
| Total liabilities | 7 | 30 | 17 | 16 | 77 | 289 |
| Shareholders' equity | 215 | 746 | 655 | 605 | 464 | 306 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | 10.1% | — |
| Operating margin | — | — | — | — | −7,527.3% | −338.7% |
| Net margin | — | — | — | — | −7,213.8% | −325.3% |
| Free cash flow margin | — | — | — | — | −1,656.5% | −288.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | 410.5% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −18.1% | −14.9% | −12.0% | −106.3% | −53.2% |
| Return on assets | — | −17.4% | −14.4% | −11.7% | −97.7% | −36.0% |
| Net debt to EBITDA | — | — | — | — | — | — |